We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1772:HKEXGanfeng Lithium Group Co., Ltd. Analysis

Data as of 2026-05-24 - not real-time

HK$68.20

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ganfeng Lithium is trading just above a recently identified support level, with the 20‑day SMA comfortably above the 50‑day SMA, indicating a short‑term bullish bias despite a bearish MACD histogram and a 14‑day RSI that sits in the lower half of its range, hinting at some oversold pressure. Volatility remains elevated at over 60% on a 30‑day basis, yet the stock’s beta is below one, suggesting price swings are less correlated with the broader market and may present opportunistic entry points. Fundamentally, the company delivers strong top‑line growth and solid operating margins, but carries a high debt load and negative free cash flow, which tempers the upside.
Analyst consensus is bullish with a “buy” recommendation and price targets in the mid‑80s HKD, implying upside from current levels, while the DCF model flags the current price as above intrinsic value, rendering the stock potentially overvalued on a pure valuation basis. The modest dividend payout and low payout ratio support dividend sustainability, and the company’s exposure to the rapidly expanding lithium market underpins a longer‑term growth narrative despite regulatory and geographic headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • price hovering near technical support
  • bearish MACD divergence
  • elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • strong revenue growth and operating margins
  • analyst price targets indicating upside
  • low payout ratio supporting dividend sustainability

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • long‑term lithium demand growth
  • high leverage and negative free cash flow
  • regulatory and geopolitical exposure in China

Key Metrics & Analysis

Financial Health

Revenue Growth143.80%
Profit Margin13.35%
P/E Ratio32.0
ROE7.34%
ROA1.52%
Debt/Equity73.61
P/B Ratio2.7
Op. Cash FlowHK$5.3B
Free Cash FlowHK$-6555274240

Technical Analysis

TrendBullish
RSI36.6
SupportHK$66.70
ResistanceHK$91.20
MA 20HK$79.51
MA 50HK$74.13
MA 200HK$54.93
MACDBearish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair ValueHK$49.47
Target PriceHK$83.83
Upside/Downside22.91%
GradeOvervalued
TypeGrowth
Dividend Yield0.25%

Risk Assessment

Beta0.59
Volatility61.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.